Evidence map›Paper›PMID 38616757›Full record

ArticleCurrent drug discovery technologies2025

New 1,3,4‒oxadiazole Quinazolines as Potential Anticancer Agents: Design, Synthesis, Biological Evaluation, and

Venkanna Gujja, Kumaraswamy Sadineni, Shiva Kumar Koppula, Avanthi Basireddy, Banothu Venkanna, Shravan Kumar Gunda

Abstract read
PubMed Publisher
In one paragraph

Article in Current drug discovery technologies, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Venkanna GujjaDepartment of Chemistry, Gitam Deemed to be University, Hyderabad campus, Rudraram, Sangareddy, Hyderabad, 502329, Telangana, India.ORCID 0009-0000-6070-4649
Kumaraswamy SadineniDepartment of Chemistry, Gitam Deemed to be University, Hyderabad campus, Rudraram, Sangareddy, Hyderabad, 502329, Telangana, India.ORCID 0009-0007-9794-1374
Shiva Kumar KoppulaDepartment of Chemistry, Gitam Deemed to be University, Hyderabad campus, Rudraram, Sangareddy, Hyderabad, 502329, Telangana, India.
Avanthi BasireddyDepartment of Chemistry, School of Applied Sciences and Humanities, VFSTR (Deemed to be University), Vadlamudi, Guntur, Andhra Pradesh, 522213, India.ORCID 0000-0002-7219-9018
Banothu VenkannaCentre for Biotechnology, Institute of Science and Technology, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, 500085, Telangana, India.
Shravan Kumar GundaBioinformatics Division, PGRRCDE, Osmania University, Tarnaka, Hyderabad, 500007, Telangana, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA novel series of 1,3,4‒oxadiazole connected to derivatives of quinazolinone (7a-e and 8a-f) was synthesized in the current investigation, and its anticancer and Topoisomerase‒ II inhibitory activity was evaluated.

objectiveThese findings inspired the design, synthesis, and biological analysis of these 1,3,4‒oxadiazole-quinazolinone analogues as antiproliferative Topo‒II inhibitors.

methodsThe novel compound structures were determined using mass spectrometry and spectral methods (IR, NMR:

resultsIn the experiment for antiproliferative activity, compounds 7d, 7e, 8c, 8e, and 8f demonstrated encouraging cytotoxicity findings against HCT‒116 and HepG2 cancer cell lines, with IC

conclusionNew findings have discovered the fact that fused 1,3,4‒oxadiazole bearing quinazolinone contributed great significance in the field of medicinal chemistry due to their diverse biological properties. Finally, the

Indexed as

Antineoplastic AgentsDNA Topoisomerases, Type IIDrug DesignMolecular Docking SimulationOxadiazolesQuinazolinesTopoisomerase II InhibitorsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorHumansStructure-Activity Relationship1,3,4-oxadiazoleAntineoplastic AgentsDNA Topoisomerases, Type IIOxadiazolesQuinazolinesTopoisomerase II Inhibitors12-amino-3-methylbenzoic acid34‒OxadiazoleADMET.antiproliferative activityformamidetopo II inhibitors

Identifiers

PMID38616757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.